Literature DB >> 11801579

Amphotericin B nephrotoxicity.

Gilbert Deray1.   

Abstract

The use of amphotericin B limited by dose-dependent nephrotoxicity. Elevated creatinine associated with amphotericin B is not only a marker for renal dysfunction, but is also linked to an increase in hospital costs and a substantial risk for the use of haemodialysis and a higher mortality rate. Therefore, amphotericin B nephrotoxicity is not a benign complication and its prevention is essential. Several manipulations have been proposed to minimize amphotericin B-induced nephrotoxicity. Mannitol and frusemide administration are reported to be protective based on anecdotal observational reports. Small prospective and randomized trials do not suggest a protective effect. Three new formulations have been developed in attempts to improve both efficacy and tolerability: amphotericin B in a lipid complex (ABLC; Abelcet); amphotericin B colloidal dispersion; and liposomal amphotericin B (AmBisome). Three prospective randomized studies have clearly shown that AmBisome is less nephrotoxic than amphotericin B. In a double-blind randomized trial significantly fewer patients receiving AmBisome had nephrotoxic effects. This significant reduction in azotaemia was also observed among subgroups of patients receiving concomitant therapy with nephrotoxic agents. Moreover, there were fewer patients with hypokalaemia in the group receiving AmBisome. A recent multicentre double-blind study has shown that AmBisome (3 or 5 mg/kg/day) has a better safety profile than Abelcet (5 mg/kg). Patients in both AmBisome treatment groups experienced less chills/rigors, less nephrotoxicity based on a doubling of serum creatinine, and fewer toxic reactions resulting in discontinuation of therapy. In conclusion, amphotericin B nephrotoxicity is observed frequently. It clearly increases patient mortality. Nephrotoxicity must be recognized early, based on tubular abnormalities and a mild increase in serum creatinine. Its prevention relies on the detection and suppression of risk factors and the use of AmBisome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801579     DOI: 10.1093/jac/49.suppl_1.37

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  75 in total

1.  Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.

Authors:  Shyam Sundar; Prabhat K Sinha; Susan A Dixon; Renata Buckley; Ann K Miller; Khadeeja Mohamed; Mahir Al-Banna
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.

Authors:  Maryam Iman; Zhaohua Huang; Francis C Szoka; Mahmoud R Jaafari
Journal:  Int J Pharm       Date:  2011-01-26       Impact factor: 5.875

3.  Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.

Authors:  Maryam Iman; Zhaohua Huang; Seyedeh Hoda Alavizadeh; Francis C Szoka; Mahmoud R Jaafari
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Design of Micelle Nanocontainers Based on PDMAEMA-b-PCL-b-PDMAEMA Triblock Copolymers for the Encapsulation of Amphotericin B.

Authors:  Ivonne L Diaz; Claudia Parra; Melva Linarez; Leon D Perez
Journal:  AAPS PharmSciTech       Date:  2015-02-11       Impact factor: 3.246

5.  Liposomal Amphotericin B and HIV-Associated Visceral Leishmaniasis : Concerns about Nephrotoxicity and Administration Schedule.

Authors:  Sergio Sabbatani; Roberto Manfredi; Ginevra Marinacci; Michele Pavoni; Michele Nafissi; Francesco Chiodo
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

6.  Endogenous Aspergillus versicolor endophthalmitis in an immuno-competent HIV-positive patient.

Authors:  Paolo Perri; Claudio Campa; Carlo Incorvaia; Francesco Parmeggiani; Giuseppe Lamberti; Ciro Costagliola; Adolfo Sebastiani
Journal:  Mycopathologia       Date:  2005-10       Impact factor: 2.574

Review 7.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 8.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan.

Authors:  Sarah Kagan; Diana Ickowicz; Miriam Shmuel; Yoram Altschuler; Edward Sionov; Miriam Pitusi; Aryeh Weiss; Shimon Farber; Abraham J Domb; Itzhack Polacheck
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

10.  A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants.

Authors:  Ga Won Jeon; Soo Hyun Koo; Jang Hoon Lee; Jong Hee Hwang; Sung Shin Kim; Eun Kyung Lee; Wook Chang; Yun Sil Chang; Won Soon Park
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.